X0202 SCHEDULE 13G 0002086593 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 06/30/2026 0002114044 Hemab Therapeutics Holdings, Inc. 423494103 101 Main Street Suite 1220 Cambridge MA 02142 Rule 13d-1(d) Sofinnova Crossover II SLP b I0 2511212.00 0.00 2511212.00 0.00 2511212.00 N 5.4 OO Note to Items 5 and 6: Sofinnova Partners SAS, a French corporation ("SP SAS"), the management company of Sofinnova Crossover II SLP ("SC"), may be deemed to have sole voting power, and Antoine Papiernik ("Papiernik"), Cedric Moreau ("Moreau"), Kinam Hong ("Hong"), Joseph Anderson ("Anderson") and David Evans ("Evans") the members of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Moreau, Hong, Anderson and Evans, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026. Sofinnova Partners SAS, a French corporation b I0 2511212.00 0.00 2511212.00 0.00 2511212.00 N 5.4 OO Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and the members of the investment committee of SC, may be deemed to have shared power to vote its shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and the members of the investment committee of SC, may be deemed to have shared power to dispose of its shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026. Antoine Papiernik b I0 2511212.00 0.00 2511212.00 0.00 2511212.00 N 5.4 IN Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026. Cedric Moreau b I0 2511212.00 0.00 2511212.00 0.00 2511212.00 N 5.4 IN Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026. Kinam Hong b X1 2511212.00 0.00 2511212.00 0.00 2511212.00 N 5.4 IN Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Hong, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Hong, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026. Joseph Anderson b X0 2511212.00 0.00 2511212.00 0.00 2511212.00 N 5.4 IN Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026. David Evans b I0 2511212.00 0.00 2511212.00 0.00 2511212.00 N 5.4 IN Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Evans, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Evans, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026. Hemab Therapeutics Holdings, Inc. 101 Main Street Suite 1220 Cambridge, MA, 02142 The persons and entities filing this Schedule 13G are Sofinnova Crossover II SLP ("SC"), Sofinnova Partners SAS ("SP SAS"), and Antoine Papiernik ("Papiernik"), Cedric Moreau ("Moreau), Kinam Hong ("Hong"), Joseph Anderson ("Anderson") and David Evans ("Evans"), the members of the investment committee of SC, (together with SC and SP SAS, the "Filing Persons"). SP SAS is the management company of SC. The address of the principal place of business for each of the Filing Persons is Sofinnova Partners SAS, 7-11 boulevard Hausmann 75009 Paris, France. SC is a French Partnership. SP SAS is a French Corporation. Papiernik, Moreau and Evans are French citizens. Hong is a U.S. citizen. Anderson is a British citizen. Y See Row 9 of the cover page for each of the Filing Persons, which is incorporated herein by reference. The filing of this Schedule 13G shall not be construed as an admission by Papiernik, Moreau, Hong, Anderson and Evans that such person is, for the purposes of Section 13(d) of the Securities Exchange Act of 1934, the beneficial owner of any securities covered by this Statement. See Row 11 of the cover page for each of the Filing Persons, which is incorporated herein by reference. Ownership is stated as of June 30, 2026, and the ownership percentages are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as disclosed by Hemab Therapeutics, Inc. in its Form 10-Q filed with the SEC on May 21, 2026. See Row 5 of the cover page for each of the Filing Persons, which is incorporated herein by reference. See Row 6 of the cover page for each of the Filing Persons, which is incorporated herein by reference. See Row 7 of the cover page for each of the Filing Persons, which is incorporated herein by reference. See Row 8 of the cover page for each of the Filing Persons, which is incorporated herein by reference. Y Y Y Y Y Y Exhibit 1 - Joint Filing Agreement Sofinnova Crossover II SLP Antoine Papiernik 08/05/2026 Sofinnova Partners SAS, a French corporation Antoine Papiernik 08/05/2026 Antoine Papiernik Antoine Papiernik 08/05/2026 Cedric Moreau Cedric Moreau 08/05/2026 Kinam Hong Kinam Hong 08/05/2026 Joseph Anderson Joseph Anderson 08/05/2026 David Evans David Evans 08/05/2026